Superworth

Embecta revenue EMBC

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$1B
Latest quarter, Q3 FY26
$271.7M
−8% on a year earlier
Fiscal year 2025
$1.1B
−4% on the year before

Embecta's revenue was $1B over the twelve months to Jun 30, 2026, down 8% on a year earlier.

In its latest quarter, Q3 FY26, it was $271.7M, down 8% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$1.1B−4%
FY2024$1.1B+0%
FY2023$1.1B−1%
FY2022$1.1B−3%
FY2021$1.2Bn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$271.7M−8%$1B
Q2 FY26$221.8M−14%$1B
Q1 FY26$261.2M−0%$1.1B
Q4 FY25$264M−8%$1.1B
Q3 FY25$295.5M+8%$1.1B
Q2 FY25$259M−10%$1.1B
Q1 FY25$261.9M−6%$1.1B
Q4 FY24$286.1M+1%$1.1B
Q3 FY24$272.5M−5%$1.1B
Q2 FY24$287.2M+4%$1.1B
Q1 FY24$277.3M+1%$1.1B
Q4 FY23$281.9M+3%$1.1B

Against its peers

Companies in Medical - Instruments & Supplies nearest Embecta's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
EMBCEmbecta$1B−8% a year
INFUInfuSystem$143.3M+2% a year
TCMDTactile Systems Technology$350.3M+17% a year
MDXGMimedx$355.2M−2% a year
UTMDUtah Medical Products$36.1M−7% a year
MOVMovado$689.9M+5% a year
PDEXPro DEX$77.5M+16% a year
IRMDIradimed$86.3M+11% a year
STAAStaar Surgical$339.6M+51% a year
BVSBioventus$581.8M+3% a year
CDRECadre$685.6M+20% a year
Peer median$345M

Where Embecta ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Embecta

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.